[PDF] Top 20 Uso, efectividad y alcance de la comunicación política en las redes sociales

... Both sarilumab regimens demonstrated to significantly reduce concentrations of joint inflammation (eg, MMP-3, C1M, and C3M) and induced changes in collagen degradation marker ...Furthermore, sarilumab 200 ... See full document

... Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy associated with psoriasis ...the treatment of Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, axial ... See full document

... In the AD molecular signaling, a critical role is played by the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway that is activated by the aforementioned Th2 cytokines, IL-4, IL-5 and ... See full document

... idiopathic arthritis (JIA), sarcoidosis, Behçets disease, inflammatory bowel disease, and the spon- dyloarthropathies (often associated with human leukocyte antigen-B27), as well as noninfectious idiopathic ...the ... See full document

... indications. At the moment, it represents an effective biologic agent for the treatment of moderate to severe RA. As it lacks a head-to-head comparison with tocilizumab we cannot be directly sure about the ... See full document

... on treatment with a ≥ 10% decrease in circulating MET levels demonstrated increased overall survival compared to those with a < 10% decrease ...tivantinib treatment, the only biomarker thus far to ... See full document

... Pacritinib (previously known as SB-1518) is an innovative selective inhibitor of JAK2 and FLT3 providing potential in the treatment of hematological malignancies. Pacritinib has potent antiproliferative ... See full document

... the potential benefits of lebrikizumab in the treatment of patients with asthma not controlled with the currently available ...daily treatment with ICS therapy and at least one additional controller ... See full document

... the treatment of select women with ...predict treatment outcomes will be necessary to rationally direct therapy to women most likely to benefit from ... See full document

... Differently from voriconazole, isavuconazole is admin- istrated as a prodrug that is water soluble and therefore does not need the addition of cyclodextrin to IV formulations, eliminating concerns for nephrotoxicity due ... See full document

... safety profile, as the side effects reported in association with its administration are mild to moderate and usually do not affect the compliance to the treatment (Table ... See full document

... was by far the most common AE, with 86.4% of patients in the abemaciclib group reporting diarrhea compared with 24.7% in the placebo group. As in MONARCH 1, a majority of diar- rhea was grades 1 and 2, with 13.4% of ... See full document

... Second, brain disease dissemination is extremely fre- quent in ALK- and ROS1-positive NSCLC at diagnosis and during the disease course, owing both to the peculiar cellular tropism and to the limited crizotinib activity ... See full document

... resistance, potential biomarkers of activity, and issues regarding patient selection and combination therapies that may optimize use of this exciting new ... See full document

... cycle. The patients also received weekly intravenous injections of farletuzumab at 2.5 mg/kg. Following the completion of car- boplatin/PLD/farletuzumab therapy, maintenance treatment with 7.5 mg/kg farletuzumab ... See full document

... First, we conducted a literature search to identify random- ized controlled trials evaluating the efficacy of agomelatine in GAD treatment. Keywords were agomelatine, general- ized anxiety disorder, and anxiety ... See full document

... Because of the limited and preliminary nature of the stud- ies mentioned above, more detailed studies are required to determine whether minocycline is effective as an adjunctive treatment for symptoms in patients ... See full document

... to its unique mechanism of antiviral action, alisporivir is pangenotypic, provides a high barrier for development of viral resistance, and does not permit cross-resistance to direct-acting ...in ... See full document

... the potential antitumor activ- ity of selumetinib in a subset of melanoma patients such as BRAF mutant melanoma and uveal melanoma harboring GNAQ/GNA11 ...combination treatment is being investigated more ... See full document

... of treatment courses was two (range, 1–5 courses) and the median time between courses was 3 weeks (range, 3–6 ...third treatment course, of whom only one showed ... See full document